What does RESST stand for?

The presentations included results from the following studies conducted by Sepracor: -- The second long-term, placebo-controlled study examining the safety and efficacy of LUNESTA for six months of nightly use in patients with primary insomnia; -- A study in which LUNESTA was administered to patients with insomnia and co-existing major depressive disorder; -- A study in which LUNESTA was administered to patients with insomnia and co-existing rheumatoid arthritis; -- A study in which LUNESTA was administered to patients with insomnia and co-existing perimenopause/menopause symptoms; and -- The Regimen of Eszopiclone Sleep Satisfaction Trial (RESST), a patient satisfaction study.

The presentations included results from the following studies conducted by Sepracor: --The second long-term, placebo-controlled study examining the safety and efficacy of LUNESTA for six months of nightly use in patients with primary insomnia; --A study in which LUNESTA was administered to patients with insomnia and co-existing major depressive disorder; --A study in which LUNESTA was administered to patients with insomnia and co-existing rheumatoid arthritis; --A study in which LUNESTA was administered to patients with insomnia and co-existing perimenopause/menopause symptoms; and --The Regimen of Eszopiclone Sleep Satisfaction Trial (RESST), a patient satisfaction study.

Evaluation of Patient Satisfaction: Regimen of Eszopiclone Sleep Satisfaction Trial (RESST) Also presented were the results of a 2,600-patient, multi-center, open-label trial that assessed patient satisfaction with LUNESTA, investigated the epidemiology of insomnia in clinical practice, investigated the nature of insomnia complaints and sleep parameters important to patients, assessed patients' satisfaction with LUNESTA overall and with respect to these specific insomnia symptoms, assessed patient preference for LUNESTA compared to any therapy used in the previous 12 months, and evaluated the safety and tolerability of LUNESTA.